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Abstract
Background: With almost 9 million new cases each year, tuberculosis remains one of the most
feared diseases on the planet. Led by the STOP-TB Partnership and WHO, recent efforts to
combat the disease have made considerable progress in a number of countries. However, the
emergence of mutated strains of Mycobacterium tuberculosis that are resistant to the major anti-
tuberculosis drugs poses a deadly threat to control efforts. Multidrug-resistant tuberculosis (MDR-
TB) has been reported in all regions of the world. More recently, extensively drug resistant-
tuberculosis (XDR-TB) that is also resistant to second line drugs has emerged in a number of
countries. To ensure that adequate resources are allocated to prevent the emergence and spread
of drug resistance it is important to understand the scale of the problem. In this article we propose
that current methods of describing the epidemiology of drug resistant tuberculosis are not
adequate for this purpose and argue for the inclusion of population based statistics in global
surveillance data.
Discussion: Whereas the prevalence of tuberculosis is presented as the proportion of individuals
within a defined population having disease, the prevalence of drug resistant tuberculosis is usually
presented as the proportion of tuberculosis cases exhibiting resistance to anti-tuberculosis drugs.
Global surveillance activities have identified countries in Eastern Europe, the former Soviet Union
and regions of China as having a high proportion of MDR-TB cases and international commentary
has focused primarily on the urgent need to improve control in these settings. Other regions, such
as sub-Saharan Africa have been observed as having a low proportion of drug resistant cases.
However, if one considers the incidence of new tuberculosis cases with drug resistant disease in
terms of the population then countries of sub-Saharan Africa have amongst the highest rates of
transmitted MDR-TB in the world. We propose that inclusion of population based statistics in
global surveillance data is necessary to better inform debate on the control of drug resistant
tuberculosis.
Summary: Re-appraisal of global MDR-TB data to include population based statistics suggests that
the problem of drug resistant tuberculosis in sub-Saharan Africa is more critical than previously
perceived.
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Background
Control of tuberculosis (TB) remains one of the most seri-
ous challenges to global health. In 2005 there were an
estimated 8.8 million new cases and 1.6 million deaths
[1]. TB is predominantly a disease of poverty with over
80% of cases occurring in Asia or Africa. Although the
greatest numbers of patients live in the highly populous
countries of Asia the highest incidence of disease is found
in the WHO region of Africa. Nine countries in sub-Saha-
ran Africa have recently reported estimated annual inci-
dences in excess of 600 cases per 100,000 [2], a burden of
disease not witnessed since before the advent of chemo-
therapy. The continued rise of TB in this region may be
largely attributed the AIDS pandemic combined with
weak healthcare delivery systems.
A new and potentially devastating threat to TB control is
the emergence of strains that cannot be cured by standard
anti-tuberculosis drug regimens [3]. Drug resistant tuber-
culosis commonly arises through the selection of mutated
strains by inadequate chemotherapy. Resistance to at least
the two major anti-tuberculosis drugs, isoniazid and
rifampicin has been termed multidrug-resistant tubercu-
losis (MDR-TB). Treatment of MDR-TB requires pro-
longed and expensive chemotherapy using second-line
drugs of heightened toxicity. Should resistance to the sec-
ond line drugs also arise then the disease becomes virtu-
ally untreatable. Extensively drug resistant-tuberculosis
(XDR-TB) has been reported in all regions of the world
[4]. XDR-TB is defined as resistance to at least rifampicin,
isoniazid, a second line injectable drug (capreomycin,
kanamycin or amikacin) and a fluoroquinolone [5]. Con-
trol of drug resistant tuberculosis requires a strong health
infrastructure to ensure the delivery of effective therapy
coupled with surveillance and monitoring activities to
enable timely intervention to limit transmission and
spread of the disease. It is paradoxical that drug resistance
develops and flourishes in those very settings least able to
deal with it. The recent report from KwaZulu Natal Prov-
ince in South Africa of an outbreak of XDR-TB where rapid
progression to death was observed in 98% of patients
demonstrates the vulnerability of sub-Saharan Africa to
outbreaks of untreatable disease [6].
Although studies demonstrating successful treatment out-
comes for MDR-TB cases have been reported from a
number of settings [7], the allocation of resources to
detect and treat MDR-TB in poor resource settings remains
controversial [8]. Whereas some advocate that priority be
given to the effective treatment of drug sensitive disease,
thus preventing the emergence of drug resistance [9], oth-
ers argue that drug resistant cases should be detected and
treated both for the good of the individual and to reduce
ongoing transmission of drug resistant disease [10]. Inev-
itably, decisions on resource allocation are based on the
perceived burden of disease. Data on the prevalence of
drug resistant tuberculosis are currently presented as the
proportion of cases found resistant to anti-tuberculosis
drugs. This article discusses global data on multi-drug
resistant tuberculosis and argues that reporting would be
greatly improved by the inclusion of population based
statistics. The proposition is illustrated by reference to
sub-Saharan Africa which, while considered a low risk set-
ting by traditional reporting methods, is shown here to
have amongst the highest levels of transmitted MDR-TB in
the world.
Discussion
In 1994 WHO and the International Union Against
Tuberculosis and Lung Diseases (IUATLD) established a
Global Surveillance Project to standardise methodology,
collect and analyse data on the extent of drug resistance
and to monitor trends over time [11]. The project has
reported the prevalence of drug resistance as the propor-
tion of tuberculosis cases resistant to anti-tuberculosis
drugs. A number of countries in Eastern Europe and the
former Soviet Union and some regions of China have
been identified as having a high prevalence of MDR-TB
[12]. For those geographical settings in sub-Saharan Africa
for which data is available the prevalence of MDR-TB is
low. This has led to the suggestion that measures to con-
trol drug resistance in Africa should not be considered a
high priority [9]. However, the very high incidence of
tuberculosis in this region suggests that the number of
MDR-TB cases within the population and the consequent
risk of transmission may be significant. Resistance
detected in previously untreated (new) cases provides an
indication of transmission of drug resistant disease. To
this end we have undertaken a re-analysis of available sur-
veillance data to provide estimates of the incidence of
MDR-TB in previously untreated cases per 100,000 of the
population.
Drug resistance surveillance data published by the WHO
and the International Union Against Tuberculosis and
Lung Diseases Global Surveillance Project was used to
estimate the incidence of previously untreated TB cases
having multi-drug resistant disease. Data was sourced
from the WHO/IUATLD Global Project on Anti-Tubercu-
losis Drug Resistance Surveillance reports of 2000 and
2004 [12,13]. The estimated incidence of tuberculosis for
the year when the surveillance was carried out and the
proportion of cases found MDR were used to calculate the
incidence of MDR-TB per 100,000 of the population.
Where necessary, population data was supplemented by
reference to the US Census Bureau's International Data
Base [14]. To allow estimation of the incidence of MDR-
TB cases arising from transmission only data from previ-
ously untreated (new) cases were selected for analysis.
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The following formulae may be used to estimate inci-
dence of MDR-TB in the population:
Data from 97 countries or geographical settings was com-
piled and ranked according to the estimated incidence of
transmitted MDR-TB within the population. Surveys
undertaken in Andorra, Cambodia, Iceland, Luxembourg,
Malta, New Zealand, Oman, Slovenia and Switzerland
reported no MDR-TB amongst previously untreated cases.
In just over half (49/97) of the geographical settings ana-
lysed, the estimated incidence of transmitted MDR-TB was
less than 1 case per 100,000 of the population. Fourteen
geographical settings had an estimated incidence of
between one and three MDR-TB cases per 100,000: Casa-
blanca (Morocco), Guangdon Province (China), Zhejian
Province (China), Guinea, Israel, Honduras, Orel Oblast
(Russian Federation), Republic of Korea, Nepal, Nicara-
gua, Iran, Thailand, Uganda (partial survey) and Sierra
Leone. The 25 settings with an estimated incidence greater
than three per 100,000 are presented in Table 1 in
descending order of estimated incidence. The incidence of
MDR-TB as previously reported is presented for each set-
ting with a ranking to reflect the comparative degree of
resistance. Whereas Karakalpakstan has the highest esti-
mated incidence of MDR-TB at 35.3 cases per 100,000 of
the population, Kazakhstan with 14.2% has the highest
proportion of new cases that are MDR-TB. The list
includes Zambia, Mozambique, Botswana and all eight of
the South African provinces for which data was available.
Estimates of the number of MDR-TB cases were high for
each three of the Chinese settings, reflecting the large pop-
ulation of this region.
While is it reassuring that in the majority of settings sur-
veyed the estimated incidence of MDR-TB in new cases
was found to be low, the incidence in some settings is
alarming. A number of sub-Saharan countries that were
previously considered to have low burdens of drug resist-
ance were found to have amongst the highest estimated
incidence of transmitted MDR-TB in the world. KwaZulu-
Natal Province of South Africa which recently reported an
outbreak of XDR-TB [15] had reported a low proportion
of cases that were MDR (1.7%) and was previously ranked
25th in the list of high prevalence MDR-TB countries.
However, our analysis suggests that with an estimated 14
cases per 100,000 of the population it has the 4th highest
incidence of transmitted MDR-TB so far reported. We sug-
gest that while data on the proportion of cases that are
resistant to anti-tuberculosis drugs offers valuable guid-
ance on the effectiveness of first line treatment programs
it does not reflect the burden of drug resistant disease on
a community, or the scale of intervention required to
interrupt transmission. If high incidence of transmitted
MDR-TB is a risk factor for the emergence and spread of
untreatable XDR disease then interventions to control
MDR-TB are urgently needed in all settings with elevated
incidences, including those of sub-Saharan Africa.
To obtain a complete picture of the incidence or preva-
lence of MDR-TB in a population would require the inclu-
sion of MDR-TB that has emerged in previously treated
cases. Unfortunately sampling strategies for previously
treated cases varied in the reported studies, and in some
cases was not representative of the general population. In
the absence of a full data set only data on new cases were
selected for analysis. The estimated incidence of MDR-TB
in new cases may therefore be considered an underesti-
mate of the total incidence of MDR-TB. It is acknowledged
that the global picture of drug resistance is far from com-
plete as many countries in which TB is endemic have yet
to be surveyed, or were surveyed some years ago [16].
Clearly, expanded surveillance activities are urgently
needed to allow a fuller assessment of the burden of
MDR-TB across the world.
We propose that when assessing the impact of drug resist-
ance in a geographical setting it would be appropriate to
consider its incidence in terms of the population. We rec-
ommend that surveillance activities are extended to per-
mit estimation of the incidence and prevalence of drug
resistant tuberculosis in the population.
Preventing the emergence of XDR-TB is a primary concern
worldwide. The ongoing outbreak of XDR-TB and high
deaths rates witnessed in South Africa has prompted calls
for increased resources. WHO has estimated that an extra
US$ 400 million will be needed to fund global MDR-TB
and XDR-TB control activities in 2007 [17]. Unfortunately
the appeal issued by WHO for additional funds has so far
generated little response [18]. We call on the international
donor community to recognise the threat of drug resistant
tuberculosis to sub Saharan Africa and other regions of the
world and to mobilise the necessary resources for its con-
trol.
Summary
• The emergence of drug resistance is a serious threat to
global efforts to control tuberculosis.
• The practice of expressing the prevalence of MDR-TB in
a geographic setting as the proportion of cases found
resistant does not adequately reflect the burden of MDR-
TB within the community or the level of transmission of
drug resistant disease.
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Table 1: Multi-drug resistance in new cases of tuberculosis with an estimated incidence greater than 3 per 100,000 of the population ranked in order of descending incidence.
Country/Setting Date of survey Population 
surveyed
Estimated incidence 
TB per 100,000
Estimated number 
of MDR-TB cases
Estimated incidence 
MDR-TB per 100,000
% TB cases with 
MDR
Ranking by % 
MDR
Karakalpakstan (Uzbekistan) 2001–2002 1,527,009 267.4 539 35.30 13.2% 3
Kazakhstan 2001 14,831,400 155.7 3,279 22.11 14.2% 1
Mpumalanga Province (SA) 2001–2002 3,111,069 578 468 15.03 2.6% 17
Kwazulu-Natal Province (SA) 2001–2002 9,146,297 827 1,286 14.06 1.7% 25
Tomsk Oblast (Russ. Fed.) 2002 941,278 931 120 12.74 13.7% 2
North Arcot District (India) 1999 5,664,823 400 634 11.20 2.8% 16
North West Province (SA) 2002–2002 3,625,924 486 388 10.69 2.2% 20
Limpopo Province (SA) 2001–2002 5,683,605 443 604 10.63 2.4% 19
Free State Province (SA) 2001–2002 2,834,519 530 270 9.54 1.8% 24
Gauteng Province (SA) 2001–2002 8,020,408 670 752 9.38 1.4% 27
Hubei Province (China) 1999 59,165,000 440 5,467 9.24 2.1% 21
Mozambique 1998–1999 16,916,638 254 1,504 8.89 3.5% 13
Eastern Cape Province (SA) 2001–2002 7,001,260 875 613 8.75 1.0% 31
Zambia 2000 10,205,0002 475 891 8.55 1.8% 24
Western Cape Province (SA) 2001–2002 4,255,743 932 357 8.39 0.9% 32
Liaoning Province (China) 1999 40,900,000 80 3,403 8.32 10.4% 4
Peru 1999 25,232,226 265 2,006 7.95 3.0% 14
Latvia 2000 237,300 821 181 7.63 9.3% 6
Lithuania 2002 3,487,000 74.7 245 7.02 9.4% 5
Estonia 2000 1,369,515 55.51 93 6.77 12.2% 3
Botswana 2002 1,680,863 620 83 4.96 0.8% 33
Ivanovo Oblast (Russian 
Fed.)
1998 1,271,100 52 59 4.68 9.0% 7
Dashoguz Velayat 
(Turkmenistan)
2001–2002 1,141,900 92.9 40 3.53 3.8% 12
Raichur District (India) 1999 1,783,822 127 57 3.18 2.5% 18
Henan Province (China) 2001 94,350,000 38.51 2,833 3.00 7.8% 8
1 "Notification all cases" estimated incidence rate not available. 2 Population from US Census Bureau's International Data Base. SA = Republic of South Africa.
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• We recommend that global surveillance activities are
expanded to include population based statistics on the
incidence and prevalence of MDR-TB.
• Re-appraisal of global drug resistance data suggests that
the problem of drug resistant tuberculosis in sub-Saharan
Africa is more critical than previously perceived.
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